What Advisors Need to Know About the First Autism ETF

As autism diagnoses rise, and research, regulation, and public awareness reshape the landscape, a broader neurodiversity care ecosystem is taking shape. The opportunities and challenges emerging from that shift were at the heart of a recent discussion among Kirsten Chang, senior industry analyst at VettaFi, Brendan Cavanaugh, chief strategy officer at Defiance ETFs, and Jane Edmondson, head of index product strategy at VettaFi.Key Takeaways The Defiance Autism Impact ETF (ASD) targets companies across healthcare, diagnostics, and education. Defiance ETFs plans to donate 100% of net advisory profits during ASD’s first two years and at least 50% thereafter to autism care and research organizations. The underlying VettaFi index, the VettaFi Autism Impact Index, equally weights 38 global companies. Economic Impact of the Autism Care Economy Experts attribute the rise in autism diagnoses to broader awareness, improved screening, and expanded diagnostic practices. But as more people are diagnosed, the scale of the care needs — and the economic costs associated with them — has become increasingly difficult to overlook. The annual societal cost of autism care in the U.S. was projected to reach $461 billion by 2025, while lifetime costs are estimated at $3.2 million per person. The complexity of care is also significant: More than 85% of people diagnosed with autism experience at least one co-occurring physical, neurological, or psychological condition. Yet the treatment landscape remains limited. There are currently no FDA-approved drugs for the core symptoms of autism spectrum disorder, leaving much of care focused on behavioral, educational, and supportive interventions. At the same time, policy support is expanding. Autism coverage mandates are now in place in 46 states, while Medicaid, the Affordable Care Act, and federal mental health parity rules provide additional avenues for coverage. The federal Autism CARES Act further supports research and services, providing between $250 million and $350 million annually to the National Institutes of Health through 2029. Together, these trends point to a care ecosystem that is growing in response to rising demand, even as significant gaps remain in treatment and access.Inside the Defiance Autism Impact ETF (ASD) Defiance ETFs launched the Defiance Autism Impact ETF (ASD) on June 1, 2026. The fund has a 0.79% gross expense ratio. Its strategy focuses on three areas: Drugs and behavioral therapeutics: Biopharmaceuticals, clinical care, speech therapy, occupational therapy, and applied behavior analysis. Diagnostics and assessment: Digital, AI-based, clinical and genetic screening technologies. Specialized education and EdTech: Learning platforms and educational tools designed for neurodivergent students. Defiance plans to donate 100% of net advisory profits during the first two years and at least 50% thereafter to autism care and research organizations. See More: Inside ASD: The Story Behind the First Autism ETFHow the VettaFi Autism Impact Index (VASDX) WorksThe rules-based index targets publicly traded companies in developed markets that play a material role in neurodiversity care. VettaFi screens companies using factors such as clinical trial activity, product indications, and revenue exposure. Eligible companies must have at least $250 million in market capitalization and meet liquidity requirements. The index equally weights its holdings, limiting the influence of large pharmaceutical companies and spreading exposure across large-, mid- and small-cap stocks. The index reconstitutes twice a year and rebalances quarterly. North America represents about 58% of the index. Europe accounts for 17%, while Asia represents 13%. Holdings include Definium Therapeutics, Neuren Pharmaceuticals, LifeStance Health Group, Otsuka Holdings, ACADIA Pharmaceuticals, and Pearson. The index returned 15.84% year-to-date through August 2026. Its three-year annualized return was 18.69% based on historical index data.Portfolio Role of Autism ETFs for Advisors Cavanaugh outlined several ways advisors could use ASD. First, advisors can add the ETF as a healthcare satellite position to complement broader healthcare exposure. Second, ASD provides access to global companies across healthcare and education through a single ticker. The strategy may also support client conversations around values and neurodiversity. Nearly two-thirds of webcast respondents said special needs, neurodiversity, and long-term care topics arise in client planning discussions. More than 55% also reported seeing greater public awareness and funding for autism over the past decade. The theme represents a long-term structural opportunity driven by changes in diagnosis, care access, and government funding. For more news, information, and analysis, visit the Thematic Investing Content Hub. VettaFi LLC (“VettaFi”) is the index provider for ASD, for which it receives an index licensing fee. However, ASD is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of ASD.